Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Longbin Liu

Showing results (51-60 of 60) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 60 results.
Nature|November 15, 2013
Antidiabetic effects of glucokinase regulatory protein small-molecule disruptorsDavid J Lloyd, David J St Jean, Robert J M Kurzeja, et al.
Journal of Medicinal Chemistry|November 10, 2015
Discovery and Structure-Guided Optimization of Diarylmethanesulfonamide Disrupters of Glucokinase-Glucokinase Regulatory Protein (GK-GKRP) Binding: Strategic Use of a N → S (nN → σ*S-X) Interaction for Conformational ConstraintLewis D Pennington, Michael D Bartberger, Michael D Croghan, et al.
Journal of Medicinal Chemistry|May 3, 2012
Structure-based design of a novel series of potent, selective inhibitors of the class I phosphatidylinositol 3-kinasesAdrian L Smith, Noel D D'Angelo, Yunxin Y Bo, et al.
Journal of Medicinal Chemistry|August 5, 2021
[<sup>11</sup>C]CHDI-626, a PET Tracer Candidate for Imaging Mutant Huntingtin Aggregates with Reduced Binding to AD Pathological ProteinsLongbin Liu, Peter D Johnson, Michael E Prime, et al.
Journal of Medicinal Chemistry|December 22, 2022
Design and Evaluation of [<sup>18</sup>F]CHDI-650 as a Positron Emission Tomography Ligand to Image Mutant Huntingtin AggregatesLongbin Liu, Peter D Johnson, Michael E Prime, et al.
Journal of Medicinal Chemistry|August 18, 2012
Selective class I phosphoinositide 3-kinase inhibitors: optimization of a series of pyridyltriazines leading to the identification of a clinical candidate, AMG 511Mark H Norman, Kristin L Andrews, Yunxin Y Bo, et al.
Journal of Medicinal Chemistry|July 7, 2025
Isoindolinone-Based PET Tracers for Imaging Mutant Huntingtin AggregatesLongbin Liu, Peter D Johnson, Matthew R Mills, et al.
Journal of Medicinal Chemistry|December 11, 2019
Discovery of a Covalent Inhibitor of KRAS<sup>G12C</sup> (AMG 510) for the Treatment of Solid TumorsBrian A Lanman, Jennifer R Allen, John G Allen, et al.
Journal of Medicinal Chemistry|September 15, 2023
Identification and Optimization of RNA-Splicing Modulators as Huntingtin Protein-Lowering Agents for the Treatment of Huntington's DiseaseLongbin Liu, Karine Malagu, Alan F Haughan, et al.
Journal of Medicinal Chemistry|July 15, 2020
Imaging Mutant Huntingtin Aggregates: Development of a Potential PET LigandLongbin Liu, Michael E Prime, Matt R Lee, et al.
Pageof 6

Showing results (51-60 of 60) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
Nature|November 15, 2013
Antidiabetic effects of glucokinase regulatory protein small-molecule disruptorsDavid J Lloyd, David J St Jean, Robert J M Kurzeja, et al.
Journal of Medicinal Chemistry|November 10, 2015
Discovery and Structure-Guided Optimization of Diarylmethanesulfonamide Disrupters of Glucokinase-Glucokinase Regulatory Protein (GK-GKRP) Binding: Strategic Use of a N → S (nN → σ*S-X) Interaction for Conformational ConstraintLewis D Pennington, Michael D Bartberger, Michael D Croghan, et al.
Journal of Medicinal Chemistry|May 3, 2012
Structure-based design of a novel series of potent, selective inhibitors of the class I phosphatidylinositol 3-kinasesAdrian L Smith, Noel D D'Angelo, Yunxin Y Bo, et al.
Journal of Medicinal Chemistry|August 5, 2021
[<sup>11</sup>C]CHDI-626, a PET Tracer Candidate for Imaging Mutant Huntingtin Aggregates with Reduced Binding to AD Pathological ProteinsLongbin Liu, Peter D Johnson, Michael E Prime, et al.
Journal of Medicinal Chemistry|December 22, 2022
Design and Evaluation of [<sup>18</sup>F]CHDI-650 as a Positron Emission Tomography Ligand to Image Mutant Huntingtin AggregatesLongbin Liu, Peter D Johnson, Michael E Prime, et al.
Journal of Medicinal Chemistry|August 18, 2012
Selective class I phosphoinositide 3-kinase inhibitors: optimization of a series of pyridyltriazines leading to the identification of a clinical candidate, AMG 511Mark H Norman, Kristin L Andrews, Yunxin Y Bo, et al.
Journal of Medicinal Chemistry|July 7, 2025
Isoindolinone-Based PET Tracers for Imaging Mutant Huntingtin AggregatesLongbin Liu, Peter D Johnson, Matthew R Mills, et al.
Journal of Medicinal Chemistry|December 11, 2019
Discovery of a Covalent Inhibitor of KRAS<sup>G12C</sup> (AMG 510) for the Treatment of Solid TumorsBrian A Lanman, Jennifer R Allen, John G Allen, et al.
Journal of Medicinal Chemistry|September 15, 2023
Identification and Optimization of RNA-Splicing Modulators as Huntingtin Protein-Lowering Agents for the Treatment of Huntington's DiseaseLongbin Liu, Karine Malagu, Alan F Haughan, et al.
Journal of Medicinal Chemistry|July 15, 2020
Imaging Mutant Huntingtin Aggregates: Development of a Potential PET LigandLongbin Liu, Michael E Prime, Matt R Lee, et al.
Pageof 6